Mahesh Karande, Omega Therapeutics CEO

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Omega Ther­a­peu­tics, a com­pa­ny de­sign­ing ge­net­ic med­i­cines that di­al the out­put of genes up or down, on Tues­day morn­ing re­vealed the first da­ta from a clin­i­cal tri­al of its so-called epige­nom­ic con­trollers.

The treat­ment re­press­es the no­to­ri­ous MYC gene, which is linked to many can­cers but has proven dif­fi­cult to tar­get. The com­pa­ny test­ed two dos­es of its ther­a­py in eight peo­ple with he­pa­to­cel­lu­lar car­ci­no­ma — the most com­mon form of liv­er can­cer — or oth­er sol­id tu­mors where MYC is of­ten a cul­prit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.